URMC / Research / Health Research /Clinical Trials / Study Details

100510 / Duke University / Consolidation RT in DLBcL / Louis Constine

Research Question:
Evaluate whether a reduction in radiation dose and field size will maintain a high rate of local control while minimizing the risk of acute and late toxicity .

Basic Study Information

Purpose:
This phase II study will evaluate whether a reduction in radiation dose and field size will maintain a high rate of local control while minimizing the risk of acute and late toxicity . Hypothesis: The radiation dose and treatment volume can be safely reduced from 30 Gy to 20 Gy while maintaining high rates of local control in patients who had a negative PET-CT scan following rituximab - containing chemotherapy.

Location: University of Rochester James P. Wilmot Cancer Institute
Study Reference #: RLYM19037

Lead Researcher (Principal Investigator)

Lead Researcher: Louis Constine

Study Contact Information

Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu

Additional Study Details

Contact This Study

First Name *

This field is required

Middle Name

Last Name *

This field is required

Phone Number

I agree to be contacted by The University of Rochester Medical Center regarding participation in this study. *

You must agree to be contacted to continue.

Please call me during the day.

Please call me during the evening.

Message

Return to Search

Research

UR Health Research